Cargando…
The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial
OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional syn...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390769/ https://www.ncbi.nlm.nih.gov/pubmed/32931984 http://dx.doi.org/10.1016/j.semarthrit.2020.07.014 |
_version_ | 1783564509790601216 |
---|---|
author | Scott, David Ibrahim, Fowzia Hill, Harry Tom, Brian Prothero, Louise Baggott, Rhiannon R. Bosworth, Ailsa Galloway, James B. Georgopoulou, Sofia Martin, Naomi Neatrour, Isabel Nikiphorou, Elena Sturt, Jackie Wailoo, Allan Williams, Frances M.K. Williams, Ruth Lempp, Heidi |
author_facet | Scott, David Ibrahim, Fowzia Hill, Harry Tom, Brian Prothero, Louise Baggott, Rhiannon R. Bosworth, Ailsa Galloway, James B. Georgopoulou, Sofia Martin, Naomi Neatrour, Isabel Nikiphorou, Elena Sturt, Jackie Wailoo, Allan Williams, Frances M.K. Williams, Ruth Lempp, Heidi |
author_sort | Scott, David |
collection | PubMed |
description | OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. METHODS: A 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. RESULTS: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. INTERPRETATION: The trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms. |
format | Online Article Text |
id | pubmed-7390769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | W.B. Saunders |
record_format | MEDLINE/PubMed |
spelling | pubmed-73907692020-07-30 The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial Scott, David Ibrahim, Fowzia Hill, Harry Tom, Brian Prothero, Louise Baggott, Rhiannon R. Bosworth, Ailsa Galloway, James B. Georgopoulou, Sofia Martin, Naomi Neatrour, Isabel Nikiphorou, Elena Sturt, Jackie Wailoo, Allan Williams, Frances M.K. Williams, Ruth Lempp, Heidi Semin Arthritis Rheum Article OBJECTIVES: Many trials have shown that intensive management is effective in patients with early active rheumatoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care who have established, moderately active RA and are already taking conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from intensive management and, in particular, achieve more remissions. METHODS: A 12-month multicentre individually randomised trial compared standard care with monthly intensive management appointments which was delivered by specially trained healthcare professionals and incorporated monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary outcomes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear regression analyses compared treatment arms with multiple imputation used for missing data. RESULTS: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care); 303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remissions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI: -24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard care =11) or other adverse events (114 vs 151) significantly increase with intensive management. INTERPRETATION: The trial shows that intensive management incorporating psychosocial support delivered by specially trained healthcare professions is effective in moderately active established RA. More patients achieve remissions, there were greater improvements in fatigue, and there were no more harms. W.B. Saunders 2020-10 /pmc/articles/PMC7390769/ /pubmed/32931984 http://dx.doi.org/10.1016/j.semarthrit.2020.07.014 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Scott, David Ibrahim, Fowzia Hill, Harry Tom, Brian Prothero, Louise Baggott, Rhiannon R. Bosworth, Ailsa Galloway, James B. Georgopoulou, Sofia Martin, Naomi Neatrour, Isabel Nikiphorou, Elena Sturt, Jackie Wailoo, Allan Williams, Frances M.K. Williams, Ruth Lempp, Heidi The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title | The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title_full | The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title_fullStr | The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title_full_unstemmed | The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title_short | The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial |
title_sort | clinical effectiveness of intensive management in moderate established rheumatoid arthritis: the titrate trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390769/ https://www.ncbi.nlm.nih.gov/pubmed/32931984 http://dx.doi.org/10.1016/j.semarthrit.2020.07.014 |
work_keys_str_mv | AT scottdavid theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT ibrahimfowzia theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT hillharry theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT tombrian theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT protherolouise theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT baggottrhiannonr theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT bosworthailsa theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT gallowayjamesb theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT georgopoulousofia theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT martinnaomi theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT neatrourisabel theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT nikiphorouelena theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT sturtjackie theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT wailooallan theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT williamsfrancesmk theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT williamsruth theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT lemppheidi theclinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT scottdavid clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT ibrahimfowzia clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT hillharry clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT tombrian clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT protherolouise clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT baggottrhiannonr clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT bosworthailsa clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT gallowayjamesb clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT georgopoulousofia clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT martinnaomi clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT neatrourisabel clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT nikiphorouelena clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT sturtjackie clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT wailooallan clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT williamsfrancesmk clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT williamsruth clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial AT lemppheidi clinicaleffectivenessofintensivemanagementinmoderateestablishedrheumatoidarthritisthetitratetrial |